For instance, pembrolizumab is known and approved for the treatment of R/M HNSCC because of its antitumor effect that is enriched in HNSCC patients with a certain level of PD-L1 expression in their tumor. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.